Neoadjuvant nivolumab shows long-term benefit in NSCLC

Hopkins physicians achieve 95% cure rate for sickle cell disease with bone marrow transplant

A reduced-intensity bone marrow transplant regimen provides durable engraftment with low rejection rates and also may preserve fertility, according to researchers at Johns Hopkins Kimmel Cancer Center.

May 08, 2026

Vol.52 No.18

Clinical Roundup

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first-in-the-world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment.

May 08, 2026

Vol.52 No.18

Clinical Roundup

Inherited long telomeres may drive broad risk for lymphoid cancers, Hopkins-led study finds

Researchers at the Johns Hopkins Kimmel Cancer Center have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically “younger” for longer than normal, predisposing affected individuals to lymphoma and other cancers.

May 08, 2026

Vol.52 No.18

Drugs & Targets

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA has accepted a New Drug Application for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab. The Prescription Drug User Fee Act target action date is Feb. 27, 2027.

May 01, 2026

Vol.52 No.17

Clinical Roundup

Johns Hopkins-led study shows how bacterial toxin drives colon tumor formation

A multicenter research team led by Johns Hopkins Medicine have identified a protein called claudin-4 that binds to the B. fragilis toxin receptor, a toxin which is known to drive colon tumor formation.

April 24, 2026

Vol.52 No.16

Drugs & Targets

Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

Nuvalent announced the submission of a New Drug Application to FDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive non-small cell lung cancer.

April 10, 2026

Vol.52 No.14

Neoadjuvant nivolumab shows long-term benefit in NSCLC

YOU MAY BE INTERESTED IN

Hopkins physicians achieve 95% cure rate for sickle cell disease with bone marrow transplant

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Inherited long telomeres may drive broad risk for lymphoid cancers, Hopkins-led study finds

FDA accepts NDA for zipalertinib for NSCLC with mutations

Johns Hopkins-led study shows how bacterial toxin drives colon tumor formation

Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login